BioWorld MedTech

June 12, 2013

ArthroCare seen as take-out target, despite legal overhang

ArthroCare (Austin, Texas) shares may be trading less on fundamentals and more on the firm's take-out potential, according to Canaccord Genuity (Toronto) analyst William Plovanic. The med-tech analyst penned his thoughts regarding ArthroCare as a take-out target in a 13-page report released Tuesday. Read More

Navidea receives favorable results in Lymphoseek study

International report: Abbott initiates ABSORB BVS clinical trial in Japan

Washington roundup: Medicare coverage tougher for devices, but also tougher for all

Financings roundup: Enzo Biochem line of credit could be increased to $12M

BioWorld Today and Medical Device Daily Webinar

Agreements/contracts: IncellDx works with Kindstar in diagnostic testing service

HIT roundup: GE Healthcare to invest $2B in software solutions

Court report: Palomar enters into MOU with plaintiffs in class action suit

People in the News

Med-Tech Notes

Product Briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...